Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, has closed a GBP2.14 million seed funding round led by Parkwalk Advisors.
University of Cambridge Seed Funds, Martlet Capital, and angel investors also contributed to the fundraise.
The funding will support the commercial development of Semarion’s SemaCyte cell assaying platform. It will also enable further expansion of the team, as Semarion recruits scientists and engineers, and establishes additional research partnerships with biopharma partners for bespoke solutions to cell screening challenges.
